Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2020-12, Vol.28 (12), p.6119-6128 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6128 |
|---|---|
| container_issue | 12 |
| container_start_page | 6119 |
| container_title | Supportive care in cancer |
| container_volume | 28 |
| creator | Choi, Jennifer Anderson, Ronald Blidner, Ada Cooksley, Tim Dougan, Michael Glezerman, Ilya Ginex, Pamela Girotra, Monica Gupta, Dipti Johnson, Douglas Shannon, Vickie R. Suarez-Almazor, Maria Rapoport, Bernardo L. Lacouture, Mario E. |
| description | Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit. |
| doi_str_mv | 10.1007/s00520-020-05706-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650995361</galeid><sourcerecordid>A650995361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-1aac8b2e9f3d29308be69ef7f5d2858bebf373523903bde25713f7909452ea183</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoqXwBzggS1zgkOKPOIkvSKsVX1IrDoWz5TiT3SmJHWzvCn4Zfw9nt7RUQsiyrPG872N7PEXxnNFzRmnzJlIqOS3pMmVD67J6UJyySoiyEUI9LE6pqlhZCSlPiicxXlPKmkbyx8WJ4K2sOWOnxa_L3ZjQmYTemZGsYvQWDxHxA7nazbMPCfdA1iYAQZdXZyGQV5erq_X6NeH5dGJHdGizfQ7GJrRAAlg_TeD6AyqSwQeStkAm48wGciIt-Ah7yNQewmSSH_3mAEn-B1pMCNkW_ETsFuy32WP2oNtih8mH-LR4NJgxwrOb9az4-v7dl_XH8uLzh0_r1UVpZcVSyYyxbcdBDaLnStC2g1rB0AyyzyXIUTeIRkguFBVdD1w2TAyNyoWTHAxrxVnx9sidd90Evc03D2bUc8DJhJ_aG9T3Mw63euP3ulWq5jXPgJc3gOC_7yAmfe13Idc6al7lf2p51bI71caMoNENPsPshNHqVS2pUlLUi-r8H6o8epjQegcD5v17Bn402OBjDDDcXpxRvfSQPvaQpstcekhX2fTi7yffWv40TRaIoyDmlNtAuHvSf7C_AbjA1NA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473382481</pqid></control><display><type>article</type><title>Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Choi, Jennifer ; Anderson, Ronald ; Blidner, Ada ; Cooksley, Tim ; Dougan, Michael ; Glezerman, Ilya ; Ginex, Pamela ; Girotra, Monica ; Gupta, Dipti ; Johnson, Douglas ; Shannon, Vickie R. ; Suarez-Almazor, Maria ; Rapoport, Bernardo L. ; Lacouture, Mario E.</creator><creatorcontrib>Choi, Jennifer ; Anderson, Ronald ; Blidner, Ada ; Cooksley, Tim ; Dougan, Michael ; Glezerman, Ilya ; Ginex, Pamela ; Girotra, Monica ; Gupta, Dipti ; Johnson, Douglas ; Shannon, Vickie R. ; Suarez-Almazor, Maria ; Rapoport, Bernardo L. ; Lacouture, Mario E.</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-020-05706-4</identifier><identifier>PMID: 32856211</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer ; Care and treatment ; Clinical medicine ; Complications and side effects ; Corticosteroids ; Cytotoxicity ; Dermatitis ; Drug Eruptions - etiology ; Drug Eruptions - pathology ; Drug Eruptions - therapy ; History, 21st Century ; Humans ; Immune Checkpoint Inhibitors - adverse effects ; Immunotherapy ; Immunotherapy - adverse effects ; International Agencies - organization & administration ; International Agencies - standards ; Ipilimumab ; Lupus ; Medical colleges ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Multinational Association of Supportive Care in Cancer (MASCC) 2020 Clinical Practice Recommendations for the Management of Immune-mediated Adverse Events from Checkpoint Inhibitors ; Neoplasms - immunology ; Neoplasms - therapy ; Nursing ; Nursing Research ; Oncology ; Pain Medicine ; Palliative Care - methods ; Palliative Care - standards ; Palliative Medicine - organization & administration ; Palliative Medicine - standards ; Pruritus ; Psoriasis ; Rehabilitation Medicine ; Severity of Illness Index ; Side effects ; Skin diseases ; Societies, Medical - organization & administration ; Societies, Medical - standards ; Special Article ; Vitiligo</subject><ispartof>Supportive care in cancer, 2020-12, Vol.28 (12), p.6119-6128</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-1aac8b2e9f3d29308be69ef7f5d2858bebf373523903bde25713f7909452ea183</citedby><cites>FETCH-LOGICAL-c541t-1aac8b2e9f3d29308be69ef7f5d2858bebf373523903bde25713f7909452ea183</cites><orcidid>0000-0001-7610-3653</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-020-05706-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-020-05706-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32856211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Jennifer</creatorcontrib><creatorcontrib>Anderson, Ronald</creatorcontrib><creatorcontrib>Blidner, Ada</creatorcontrib><creatorcontrib>Cooksley, Tim</creatorcontrib><creatorcontrib>Dougan, Michael</creatorcontrib><creatorcontrib>Glezerman, Ilya</creatorcontrib><creatorcontrib>Ginex, Pamela</creatorcontrib><creatorcontrib>Girotra, Monica</creatorcontrib><creatorcontrib>Gupta, Dipti</creatorcontrib><creatorcontrib>Johnson, Douglas</creatorcontrib><creatorcontrib>Shannon, Vickie R.</creatorcontrib><creatorcontrib>Suarez-Almazor, Maria</creatorcontrib><creatorcontrib>Rapoport, Bernardo L.</creatorcontrib><creatorcontrib>Lacouture, Mario E.</creatorcontrib><title>Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.</description><subject>Cancer</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>Complications and side effects</subject><subject>Corticosteroids</subject><subject>Cytotoxicity</subject><subject>Dermatitis</subject><subject>Drug Eruptions - etiology</subject><subject>Drug Eruptions - pathology</subject><subject>Drug Eruptions - therapy</subject><subject>History, 21st Century</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - adverse effects</subject><subject>Immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>International Agencies - organization & administration</subject><subject>International Agencies - standards</subject><subject>Ipilimumab</subject><subject>Lupus</subject><subject>Medical colleges</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Multinational Association of Supportive Care in Cancer (MASCC) 2020 Clinical Practice Recommendations for the Management of Immune-mediated Adverse Events from Checkpoint Inhibitors</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Pain Medicine</subject><subject>Palliative Care - methods</subject><subject>Palliative Care - standards</subject><subject>Palliative Medicine - organization & administration</subject><subject>Palliative Medicine - standards</subject><subject>Pruritus</subject><subject>Psoriasis</subject><subject>Rehabilitation Medicine</subject><subject>Severity of Illness Index</subject><subject>Side effects</subject><subject>Skin diseases</subject><subject>Societies, Medical - organization & administration</subject><subject>Societies, Medical - standards</subject><subject>Special Article</subject><subject>Vitiligo</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kk1v1DAQhiMEoqXwBzggS1zgkOKPOIkvSKsVX1IrDoWz5TiT3SmJHWzvCn4Zfw9nt7RUQsiyrPG872N7PEXxnNFzRmnzJlIqOS3pMmVD67J6UJyySoiyEUI9LE6pqlhZCSlPiicxXlPKmkbyx8WJ4K2sOWOnxa_L3ZjQmYTemZGsYvQWDxHxA7nazbMPCfdA1iYAQZdXZyGQV5erq_X6NeH5dGJHdGizfQ7GJrRAAlg_TeD6AyqSwQeStkAm48wGciIt-Ah7yNQewmSSH_3mAEn-B1pMCNkW_ETsFuy32WP2oNtih8mH-LR4NJgxwrOb9az4-v7dl_XH8uLzh0_r1UVpZcVSyYyxbcdBDaLnStC2g1rB0AyyzyXIUTeIRkguFBVdD1w2TAyNyoWTHAxrxVnx9sidd90Evc03D2bUc8DJhJ_aG9T3Mw63euP3ulWq5jXPgJc3gOC_7yAmfe13Idc6al7lf2p51bI71caMoNENPsPshNHqVS2pUlLUi-r8H6o8epjQegcD5v17Bn402OBjDDDcXpxRvfSQPvaQpstcekhX2fTi7yffWv40TRaIoyDmlNtAuHvSf7C_AbjA1NA</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Choi, Jennifer</creator><creator>Anderson, Ronald</creator><creator>Blidner, Ada</creator><creator>Cooksley, Tim</creator><creator>Dougan, Michael</creator><creator>Glezerman, Ilya</creator><creator>Ginex, Pamela</creator><creator>Girotra, Monica</creator><creator>Gupta, Dipti</creator><creator>Johnson, Douglas</creator><creator>Shannon, Vickie R.</creator><creator>Suarez-Almazor, Maria</creator><creator>Rapoport, Bernardo L.</creator><creator>Lacouture, Mario E.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7610-3653</orcidid></search><sort><creationdate>20201201</creationdate><title>Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors</title><author>Choi, Jennifer ; Anderson, Ronald ; Blidner, Ada ; Cooksley, Tim ; Dougan, Michael ; Glezerman, Ilya ; Ginex, Pamela ; Girotra, Monica ; Gupta, Dipti ; Johnson, Douglas ; Shannon, Vickie R. ; Suarez-Almazor, Maria ; Rapoport, Bernardo L. ; Lacouture, Mario E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-1aac8b2e9f3d29308be69ef7f5d2858bebf373523903bde25713f7909452ea183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>Complications and side effects</topic><topic>Corticosteroids</topic><topic>Cytotoxicity</topic><topic>Dermatitis</topic><topic>Drug Eruptions - etiology</topic><topic>Drug Eruptions - pathology</topic><topic>Drug Eruptions - therapy</topic><topic>History, 21st Century</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - adverse effects</topic><topic>Immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>International Agencies - organization & administration</topic><topic>International Agencies - standards</topic><topic>Ipilimumab</topic><topic>Lupus</topic><topic>Medical colleges</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Multinational Association of Supportive Care in Cancer (MASCC) 2020 Clinical Practice Recommendations for the Management of Immune-mediated Adverse Events from Checkpoint Inhibitors</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Pain Medicine</topic><topic>Palliative Care - methods</topic><topic>Palliative Care - standards</topic><topic>Palliative Medicine - organization & administration</topic><topic>Palliative Medicine - standards</topic><topic>Pruritus</topic><topic>Psoriasis</topic><topic>Rehabilitation Medicine</topic><topic>Severity of Illness Index</topic><topic>Side effects</topic><topic>Skin diseases</topic><topic>Societies, Medical - organization & administration</topic><topic>Societies, Medical - standards</topic><topic>Special Article</topic><topic>Vitiligo</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Jennifer</creatorcontrib><creatorcontrib>Anderson, Ronald</creatorcontrib><creatorcontrib>Blidner, Ada</creatorcontrib><creatorcontrib>Cooksley, Tim</creatorcontrib><creatorcontrib>Dougan, Michael</creatorcontrib><creatorcontrib>Glezerman, Ilya</creatorcontrib><creatorcontrib>Ginex, Pamela</creatorcontrib><creatorcontrib>Girotra, Monica</creatorcontrib><creatorcontrib>Gupta, Dipti</creatorcontrib><creatorcontrib>Johnson, Douglas</creatorcontrib><creatorcontrib>Shannon, Vickie R.</creatorcontrib><creatorcontrib>Suarez-Almazor, Maria</creatorcontrib><creatorcontrib>Rapoport, Bernardo L.</creatorcontrib><creatorcontrib>Lacouture, Mario E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Jennifer</au><au>Anderson, Ronald</au><au>Blidner, Ada</au><au>Cooksley, Tim</au><au>Dougan, Michael</au><au>Glezerman, Ilya</au><au>Ginex, Pamela</au><au>Girotra, Monica</au><au>Gupta, Dipti</au><au>Johnson, Douglas</au><au>Shannon, Vickie R.</au><au>Suarez-Almazor, Maria</au><au>Rapoport, Bernardo L.</au><au>Lacouture, Mario E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>28</volume><issue>12</issue><spage>6119</spage><epage>6128</epage><pages>6119-6128</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32856211</pmid><doi>10.1007/s00520-020-05706-4</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-7610-3653</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2020-12, Vol.28 (12), p.6119-6128 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996262 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Cancer Care and treatment Clinical medicine Complications and side effects Corticosteroids Cytotoxicity Dermatitis Drug Eruptions - etiology Drug Eruptions - pathology Drug Eruptions - therapy History, 21st Century Humans Immune Checkpoint Inhibitors - adverse effects Immunotherapy Immunotherapy - adverse effects International Agencies - organization & administration International Agencies - standards Ipilimumab Lupus Medical colleges Medicine Medicine & Public Health Monoclonal antibodies Multinational Association of Supportive Care in Cancer (MASCC) 2020 Clinical Practice Recommendations for the Management of Immune-mediated Adverse Events from Checkpoint Inhibitors Neoplasms - immunology Neoplasms - therapy Nursing Nursing Research Oncology Pain Medicine Palliative Care - methods Palliative Care - standards Palliative Medicine - organization & administration Palliative Medicine - standards Pruritus Psoriasis Rehabilitation Medicine Severity of Illness Index Side effects Skin diseases Societies, Medical - organization & administration Societies, Medical - standards Special Article Vitiligo |
| title | Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A28%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multinational%20Association%20of%20Supportive%20Care%20in%20Cancer%20(MASCC)%202020%20clinical%20practice%20recommendations%20for%20the%20management%20of%20severe%20dermatological%20toxicities%20from%20checkpoint%20inhibitors&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Choi,%20Jennifer&rft.date=2020-12-01&rft.volume=28&rft.issue=12&rft.spage=6119&rft.epage=6128&rft.pages=6119-6128&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-020-05706-4&rft_dat=%3Cgale_pubme%3EA650995361%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473382481&rft_id=info:pmid/32856211&rft_galeid=A650995361&rfr_iscdi=true |